CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.
Autor: | Zhang F; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Yang Q; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Tang S; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Jiang S; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Zhao Q; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Li J; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Xu C; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Liu J; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China. Electronic address: jingliu0318@aliyun.com., Fu Y; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China. Electronic address: fuyunfeng@csu.edu.cn. |
---|---|
Jazyk: | angličtina |
Zdroj: | International journal of pharmaceutics [Int J Pharm] 2023 Aug 25; Vol. 643, pp. 123241. Date of Electronic Publication: 2023 Jul 20. |
DOI: | 10.1016/j.ijpharm.2023.123241 |
Abstrakt: | Multiple myeloma (MM) is a malignant and incurable disease. Chemotherapy is currently the primary treatment option for MM. However, chemotherapeutic drugs can interrupt treatment because of serious side effects. Therefore, development of novel therapeutics for MM is essential. In this study, we designed and constructed an innovative nanoparticle-based drug delivery system, P-R@Ni Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |